Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1958 1
1959 1
1961 2
1962 2
1963 3
1965 1
1966 5
1967 2
1968 8
1969 5
1970 9
1971 3
1972 3
1973 1
1974 4
1975 6
1976 6
1977 8
1978 5
1979 3
1980 6
1981 3
1982 3
1983 5
1984 6
1985 6
1986 10
1987 7
1988 6
1989 10
1990 8
1991 3
1992 3
1993 7
1994 9
1995 6
1996 6
1997 5
1998 5
1999 1
2000 7
2001 1
2002 6
2003 7
2004 6
2005 15
2006 20
2007 11
2008 13
2009 11
2010 17
2011 11
2012 15
2013 16
2014 15
2015 4
2016 17
2017 14
2018 13
2019 26
2020 35
2021 24
2022 28
2023 26
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

523 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Brunet M, et al. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. Ther Drug Monit. 2019. PMID: 31045868 Review.
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: brunet m. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Standardized annotation of translated open reading frames.
Mudge JM, Ruiz-Orera J, Prensner JR, Brunet MA, Calvet F, Jungreis I, Gonzalez JM, Magrane M, Martinez TF, Schulz JF, Yang YT, Albà MM, Aspden JL, Baranov PV, Bazzini AA, Bruford E, Martin MJ, Calviello L, Carvunis AR, Chen J, Couso JP, Deutsch EW, Flicek P, Frankish A, Gerstein M, Hubner N, Ingolia NT, Kellis M, Menschaert G, Moritz RL, Ohler U, Roucou X, Saghatelian A, Weissman JS, van Heesch S. Mudge JM, et al. Among authors: brunet ma. Nat Biotechnol. 2022 Jul;40(7):994-999. doi: 10.1038/s41587-022-01369-0. Nat Biotechnol. 2022. PMID: 35831657 Free PMC article. No abstract available.
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Larroquette M, et al. Among authors: brunet m. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. J Immunother Cancer. 2022. PMID: 35618288 Free PMC article.
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers.
Vanhersecke L, Bougouin A, Crombé A, Brunet M, Sofeu C, Parrens M, Pierron H, Bonhomme B, Lembege N, Rey C, Velasco V, Soubeyran I, Begueret H, Bessede A, Bellera C, Scoazec JY, Italiano A, Fridman CS, Fridman WH, Le Loarer F. Vanhersecke L, et al. Among authors: brunet m. Lab Invest. 2023 May;103(5):100063. doi: 10.1016/j.labinv.2023.100063. Epub 2023 Jan 18. Lab Invest. 2023. PMID: 36801637
Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease.
Amaya-Garrido A, Brunet M, Buffin-Meyer B, Piedrafita A, Grzesiak L, Agbegbo E, Del Bello A, Ferrandiz I, Ardeleanu S, Bermudez-Lopez M, Fedou C, Camus M, Burlet-Schiltz O, Massines J, Buléon M, Feuillet G, Alves M, Neau E, Casemayou A, Breuil B, Saulnier-Blache JS, Denis C, Voelkl J, Glorieux G, Hobson S, Arefin S, Rahman A, Kublickiene K, Stenvinkel P, Bascands JL, Faguer S, Valdivielso JM, Schanstra JP, Klein J. Amaya-Garrido A, et al. Among authors: brunet m. Sci Transl Med. 2023 Sep 6;15(712):eabn5939. doi: 10.1126/scitranslmed.abn5939. Epub 2023 Sep 6. Sci Transl Med. 2023. PMID: 37672568
Cytokine-based immune monitoring.
Millán O, Brunet M. Millán O, et al. Among authors: brunet m. Clin Biochem. 2016 Mar;49(4-5):338-46. doi: 10.1016/j.clinbiochem.2016.01.004. Epub 2016 Jan 19. Clin Biochem. 2016. PMID: 26800778 Review.
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman LJ. Lemaitre F, et al. Among authors: brunet m. Ther Drug Monit. 2023 Apr 1;45(2):191-199. doi: 10.1097/FTD.0000000000001014. Ther Drug Monit. 2023. PMID: 35944126 Free article.
Pharmacodynamic Monitoring of mTOR Inhibitors.
Millán O, Wieland E, Marquet P, Brunet M. Millán O, et al. Among authors: brunet m. Ther Drug Monit. 2019 Apr;41(2):160-167. doi: 10.1097/FTD.0000000000000616. Ther Drug Monit. 2019. PMID: 30883509 Review.
523 results